<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262223</url>
  </required_header>
  <id_info>
    <org_study_id>#6266R-NIAAAHIE014341</org_study_id>
    <secondary_id>R01AA014341-06</secondary_id>
    <nct_id>NCT00262223</nct_id>
  </id_info>
  <brief_title>Combined Treatment for Alcohol-Dependent Individuals With PTSD</brief_title>
  <official_title>Combined Treatment for Alcohol-Dependent Individuals With PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This treatment intervention trial is designed for men and women with either alcohol misuse
      (e.g. hazardous or binge drinking) or alcohol use disorders (alcohol abuse or dependence) and
      comorbid PTSD. Participants will be randomly assigned to one of two treatments (a cognitive
      behavioral treatment intervention called &quot;Seeking Safety&quot; + Medication (&quot;Zoloft&quot;) or Seeking
      Safety + placebo) and will be evaluated at baseline, at completion of the treatment (12
      sessions over 12 weeks), and again at 6 months and 12 months post-treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The impetus for the current study is to contribute to the development of effective treatments
      targeted for men and women with either alcohol misuse (e.g., hazardous or binge drinking) or
      alcohol use disorders (e.g. alcohol abuse or alcohol dependence) and comorbid PTSD. Research
      findings have shown that these individuals have poorer treatment outcomes and show more
      severe symptoms than treatment seeking alcohol-misusing or alcohol dependent participants
      without PTSD. The aim of this study is to replicate and expand on 1) pilot studies
      demonstrating the effectiveness of a manualized cognitive-behavioral treatment specifically
      designed for individuals with comorbid substance use disorders and PTSD, &quot;Seeking Safety&quot; 2)
      preliminary results on the effectiveness of the antidepressant sertraline (&quot;Zoloft&quot;) for a
      dually diagnosed population and 3) the examination of the effectiveness of these
      interventions over either treatment alone. We are comparing &quot;Seeking Safety&quot; alone to
      &quot;Seeking Safety&quot; in combination with the antidepressant medication sertraline (&quot;Zoloft&quot;) in
      terms of their effectiveness in reducing alcohol use and PTSD symptoms. Participants will be
      randomly assigned to one of two treatments (Seeking Safety + Med or Seeking Safety + placebo)
      and will be evaluated at baseline, at completion of the treatment (12 sessions over 12
      weeks), and again at 6 months and 12 months post-treatment. Secondary aims of the study
      include exploring potential differences between alcoholic subtypes on treatment outcomes;
      impact of combined treatment on treatment participation and global psychiatric symptoms;
      differences in the time course and order of changes in alcohol and drug use and PTSD symptoms
      by condition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heavy Drinking Days/Week</measure>
    <time_frame>Baseline, End-of-treatment, 6-month follow-up and 12-month follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PTSD Symptom Severity / Clinician Administered PTSD Scale</measure>
    <time_frame>Baseline, End-of-treatment, 6-month follow-up and 12-month follow-up</time_frame>
    <description>Clinician Administered PTSD Scale (CAPS) is a 17-item, semi-structured interview of PTSD symptoms. Range of scores is 0-136. Five rationally derived severity score ranges for interpreting CAPS total score have been proposed: 0-19 = asymptomatic/few symptoms, 20-39 = mild PTSD/subthreshold, 40-59 = moderate PTSD/threshold, 60-79 = severe PTSD symptomatology, and &gt;80 = extreme PTSD symptomology (Weathers et. al., 2001). A 15-point change in CAPS total severity score has been proposed as a marker of clinically significant change (Weathers et. al., 2001).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alcohol Subtypes Based on Pre-morbid Risk Factors</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trajectory and Trends of Changes in Substance Use and PTSD Symptoms</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention Rates in Alcohol Treatment</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Psychiatric Severity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Stress Disorders, Post-Traumatic</condition>
  <condition>Alcohol Abuse</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>1) Seeking Safety + Sertraline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Seeking Safety + Sertraline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2) Seeking Safety + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Seeking Safety + Placebo;</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Seeking Safety</intervention_name>
    <description>Seeking Safety cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders</description>
    <arm_group_label>1) Seeking Safety + Sertraline</arm_group_label>
    <arm_group_label>2) Seeking Safety + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>An anti-depressant medication, selective serotonin reuptake inhibitor (SSRI) type</description>
    <arm_group_label>1) Seeking Safety + Sertraline</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pill placebo</intervention_name>
    <arm_group_label>2) Seeking Safety + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females who are a minimum of 18 years and maximum of 65 years.

          2. Participants meet Diagnostic and Statistical Manual Diploma in Social Medicine IV
             (DSM-IV) criteria for current alcohol misuse, abuse or dependence.

          3. Participants must have current alcohol use over past 90 days defined by more than or
             equal to 2 heavy drinking days or more than or equal to 14 drinks over 30 consecutive
             days or abstinence less than or equal to 21 consecutive days.

          4. Participants meet criteria for full or subthreshold PTSD. Subthreshold PTSD criteria
             differs from full PTSD in that the individual meets cluster C (numbing) OR cluster D
             (hyperarousal) whereas full PTSD requires that the individual meets both cluster C and
             D.

          5. Participants demonstrate no gross organic mental syndrome.

          6. Participants are capable of giving informed consent and capable of complying with
             study procedures.

          7. Participants speak English.

        Exclusion Criteria:

          1. Individuals who are at significant risk for suicide based on their current mental
             state or history.

          2. Participants with other current Axis I psychiatric disorders that, in the
             investigators' judgment, are unstable and would be disrupted by study medications.
             Current diagnosis of Bipolar I and psychotic disorders are exclusionary.

          3. Participants who are currently severely depressed.

          4. Participants with a history of psychosis or mania.

          5. Participants with organic mental syndrome.

          6. Participants physiologically dependent on any substance other than alcohol (excluding
             nicotine or caffeine or medically stable and managed methadone).

          7. Participants with comorbid substance abuse disorder who require detoxification
             treatment.

          8. Participants with unstable or significant physical disorders (e.g., uncontrolled
             hypertension, poorly-controlled diabetes, alanine aminotransferase/aspartate
             aminotransaminase (AST/ALT) three times the upper limit of normal) that would increase
             the risk of study participation.

          9. Participants with a known history of seizures (not related to alcohol withdrawal).

         10. Participants with moderate to severe alcohol withdrawal that would require
             pharmacological intervention.

         11. Participants currently taking prescribed psychotropic medication that is
             contraindicated for use with sertraline (e.g. antidepressant medications except for
             mirtazapine or trazodone when used for the treatment of insomnia ) and/or psychotropic
             medications where the participant has not achieved a stabilized regimen. Participants
             that are stable on medications that are not contraindicated with the use of sertraline
             (e.g., Methadone or Adderall) will not be excluded.

         12. A history of an allergic reaction to sertraline.

         13. Women who are currently pregnant or are trying to get pregnant or are nursing or are
             pre-menopausal and sexually active but not using effective birth control.

         14. Participants refusing to be audio or videotaped.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise A. Hien, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City College of New York &amp; New York State Psychiatric Institute/Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City College, City University of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hien DA, Levin FR, Ruglass LM, LÃ³pez-Castro T, Papini S, Hu MC, Cohen LR, Herron A. Combining seeking safety with sertraline for PTSD and alcohol use disorders: A randomized controlled trial. J Consult Clin Psychol. 2015 Apr;83(2):359-69. doi: 10.1037/a0038719. Epub 2015 Jan 26.</citation>
    <PMID>25622199</PMID>
  </results_reference>
  <results_reference>
    <citation>Ruglass LM, Pedersen A, Cheref S, Hu MC, Hien DA. Racial differences in adherence and response to combined treatment for full and subthreshold post-traumatic stress disorder and alcohol use disorders: A secondary analysis. J Ethn Subst Abuse. 2016 Oct-Dec;15(4):434-448. Epub 2015 Sep 30.</citation>
    <PMID>26422415</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2005</study_first_submitted>
  <study_first_submitted_qc>December 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2005</study_first_posted>
  <results_first_submitted>August 14, 2014</results_first_submitted>
  <results_first_submitted_qc>September 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 16, 2014</results_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Co-morbid alcohol dependence and PTSD</keyword>
  <keyword>Alcohol and other drug use disorders</keyword>
  <keyword>Treatment outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants in the metropolitan New York area were recruited through newspaper and radio advertisements, flyers, and referrals from outpatient mental health centers between April 2006 and March 2012.</recruitment_details>
      <pre_assignment_details>Individuals were screened through a brief telephone interview and then completed a baseline interview. After baseline assessment and medical clearance, eligible participants began a one-week, single-blind placebo lead-in phase. Those who completed the lead in phase were accepted into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1) Seeking Safety + Sertraline</title>
          <description>Seeking Safety + Sertraline
Seeking Safety: Seeking Safety cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders
Sertraline: An anti-depressant medication, selective serotonin reuptake inhibitor (SSRI) type</description>
        </group>
        <group group_id="P2">
          <title>2) Seeking Safety + Placebo</title>
          <description>Seeking Safety + Placebo;
Seeking Safety: Seeking Safety cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders
Sertraline: An anti-depressant medication, selective serotonin reuptake inhibitor (SSRI) type</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>1-week Post-treatment Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>6-month Post-treatment Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28">Subjects were included in subsequent follow-ups even if lost to contact during previous follow-up.</participants>
                <participants group_id="P2" count="29">Subjects were included in subsequent follow-ups even if lost to contact during previous follow-up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>12-month Post-treatment Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28">Subjects were included in subsequent follow-ups even if lost to contact during previous follow-up.</participants>
                <participants group_id="P2" count="29">Subjects were included in subsequent follow-ups even if lost to contact during previous follow-up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1) Seeking Safety + Sertraline</title>
          <description>Seeking Safety, a cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders + Setraline, an anti-depressant medication, selective serotonin reuptake inhibitor (SSRI) type</description>
        </group>
        <group group_id="B2">
          <title>2) Seeking Safety + Placebo</title>
          <description>Seeking Safety, a cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders + Pill placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="69"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" spread="9.8"/>
                    <measurement group_id="B2" value="42.5" spread="8.5"/>
                    <measurement group_id="B3" value="42.5" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Heavy Drinking Days/Week</title>
        <time_frame>Baseline, End-of-treatment, 6-month follow-up and 12-month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1) Seeking Safety + Sertraline</title>
            <description>Seeking Safety + Sertraline</description>
          </group>
          <group group_id="O2">
            <title>2) Seeking Safety + Placebo</title>
            <description>Seeking Safety + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Heavy Drinking Days/Week</title>
          <units>Days/Week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="2.17"/>
                    <measurement group_id="O2" value="2.89" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End-of-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="1.79"/>
                    <measurement group_id="O2" value="0.48" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".86" spread="1.46"/>
                    <measurement group_id="O2" value="0.75" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.47"/>
                    <measurement group_id="O2" value="0.24" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between group analyses were conducted of time-by-treatment interaction that included the four study time points (baseline, end-of-treatment, 6-mos and 12-mos).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Generalized Estimating Equations</method>
            <method_desc>Negative binomial models with log link were applied to the alcohol consumption measure.</method_desc>
            <param_type>Incidence Rate Ratio</param_type>
            <param_value>1.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>4.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PTSD Symptom Severity / Clinician Administered PTSD Scale</title>
        <description>Clinician Administered PTSD Scale (CAPS) is a 17-item, semi-structured interview of PTSD symptoms. Range of scores is 0-136. Five rationally derived severity score ranges for interpreting CAPS total score have been proposed: 0-19 = asymptomatic/few symptoms, 20-39 = mild PTSD/subthreshold, 40-59 = moderate PTSD/threshold, 60-79 = severe PTSD symptomatology, and &gt;80 = extreme PTSD symptomology (Weathers et. al., 2001). A 15-point change in CAPS total severity score has been proposed as a marker of clinically significant change (Weathers et. al., 2001).</description>
        <time_frame>Baseline, End-of-treatment, 6-month follow-up and 12-month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1) Seeking Safety + Sertraline</title>
            <description>Seeking Safety + Sertraline</description>
          </group>
          <group group_id="O2">
            <title>2) Seeking Safety + Placebo</title>
            <description>Seeking Safety + Placebo;</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Symptom Severity / Clinician Administered PTSD Scale</title>
          <description>Clinician Administered PTSD Scale (CAPS) is a 17-item, semi-structured interview of PTSD symptoms. Range of scores is 0-136. Five rationally derived severity score ranges for interpreting CAPS total score have been proposed: 0-19 = asymptomatic/few symptoms, 20-39 = mild PTSD/subthreshold, 40-59 = moderate PTSD/threshold, 60-79 = severe PTSD symptomatology, and &gt;80 = extreme PTSD symptomology (Weathers et. al., 2001). A 15-point change in CAPS total severity score has been proposed as a marker of clinically significant change (Weathers et. al., 2001).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.50" spread="20.03"/>
                    <measurement group_id="O2" value="59.50" spread="18.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End-of-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.25" spread="28.23"/>
                    <measurement group_id="O2" value="41.88" spread="29.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.09" spread="20.70"/>
                    <measurement group_id="O2" value="37.46" spread="25.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.90" spread="19.95"/>
                    <measurement group_id="O2" value="31.82" spread="24.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Generalized estimating equations (GEE) were utilized to model PTSD outcomes. This method is an extension of the generalized linear model that handles correlated data arising from repeated measurements, requires no parametric distribution assumption, and provides robust inference with respect to misspecification of the within-subject correlation. A temporal within-subjects autoregressive [AR(1)] correlation matrix was used to model participants across timepoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <p_value_desc>A trend-level time-by-treatment interaction (p = .096) was probed for simple effects, which revealed a significantly greater reduction in CAPS scores at end-of-treatment in the SS+Sertraline group relative to the SS+Placebo group.</p_value_desc>
            <method>Generalized Estimating Equations</method>
            <param_type>Parameter Estimate</param_type>
            <param_value>-16.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.18</ci_lower_limit>
            <ci_upper_limit>-1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alcohol Subtypes Based on Pre-morbid Risk Factors</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trajectory and Trends of Changes in Substance Use and PTSD Symptoms</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retention Rates in Alcohol Treatment</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Psychiatric Severity</title>
        <time_frame>1 year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Seeking Safety + Sertraline</title>
          <description>Seeking Safety, a cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders, + Setraline, an anti-depressant medication, selective serotonin reuptake inhibitor (SSRI) type</description>
        </group>
        <group group_id="E2">
          <title>Seeking Seeking + Placebo</title>
          <description>Seeking Safety, a cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders + Pill Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Serious medical illness</sub_title>
                <description>Serious medical incidents were reported to the study's institutional review boards and none were determined to be study-related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Denise A. Hien, Ph.D.</name_or_title>
      <organization>The City College of New York</organization>
      <phone>(212) 650-5666</phone>
      <email>dhien@ccny.cuny.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

